Carbon monoxide inhalation - Mallinckrodt

Drug Profile

Carbon monoxide inhalation - Mallinckrodt

Alternative Names: Covox

Latest Information Update: 04 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ikaria Holdings
  • Developer Mallinckrodt plc
  • Class Inorganic carbon compounds
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Renal transplant rejection

Most Recent Events

  • 16 Apr 2015 Ikaria Holdings has been acquired by Mallinckrodt plc
  • 28 Jul 2008 Carbon monoxide inhalation receives Orphan Drug status for Renal transplant rejection in USA
  • 15 Feb 2008 Phase-II clinical trials in Renal transplant rejection in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top